OMAHA-004: Phase 3 trial of the steroidogenesis inhibitor opevesostat versus androgen receptor pathway inhibitor (ARPI) switch in participants with metastatic castration-resistant prostate cancer after a prior ARPI

OMAHA-004: Phase 3 trial of the steroidogenesis inhibitor opevesostat versus androgen receptor pathway inhibitor (ARPI) switch in participants with metastatic castration-resistant prostate cancer after a prior ARPI

Sunday, May 17, 2026 2:52 PM to 3:00 PM · 8 min. (America/New_York)
Hall B, The Square, Learning Lab
Detail

Log in

See all the content and easy-to-use features by logging in or registering!